Respiratory

Bronchiectasis: diagnosis and chronic management

Clinical Overview and When to Suspect Bronchiectasis

— Chronic productive cough (most days, >8 weeks) with mucopurulent sputum

— Recurrent lower respiratory infections requiring repeated antibiotic courses

— Hemoptysis (recurrent, small-volume) in a patient without smoking history

— Persistent crackles or wheezing localized to the same lung region

— "Asthma" or "COPD" patient who fails to respond to standard therapy

— Unexplained bronchorrhea (>30 mL/day of sputum)

— Post-infectious: childhood pertussis, measles, severe pneumonia, TB

— Immunodeficiency: CVID, HIV, hypogammaglobulinemia

— Genetic: CF, primary ciliary dyskinesia (PCD), alpha-1 antitrypsin deficiency

— Autoimmune: rheumatoid arthritis, Sjögren, IBD

— ABPA in asthmatics, especially with central bronchiectasis

— Aspiration, foreign body, or focal obstruction (tumor)

— Non-tuberculous mycobacteria (NTM), especially MAC in "Lady Windermere" phenotype

Board pearl: A nonsmoking, thin, elderly woman with chronic cough and right middle lobe/lingular bronchiectasis on CT — think MAC pulmonary infection (Lady Windermere syndrome). Obtain three sputum AFB cultures before treating.

Step 3 management framing: Bronchiectasis is a syndrome, not a single disease — your job in the ambulatory clinic is to (1) confirm with HRCT, (2) identify a treatable etiology, (3) optimize airway clearance, and (4) prevent exacerbations. Always ask: "Why does this patient have bronchiectasis?" Etiologic workup changes management in ~40% of patients.

Definition: Permanent, abnormal dilation of bronchi due to a vicious cycle of airway inflammation, impaired mucociliary clearance, recurrent infection, and structural destruction (Cole's hypothesis).

Epidemiology: Prevalence rising in the US, especially among older women; often labeled "non-cystic fibrosis bronchiectasis" (NCFB) to distinguish from CF.

When to suspect on Step 3:

High-yield triggers that should prompt workup:

Presentation Patterns and Key History

— Chronic productive cough (>90% of patients)

— Daily mucopurulent or purulent sputum (often layered: foam, mucus, pus on standing)

— Recurrent respiratory infections with prolonged recovery

— Hemoptysis (50%) — usually scant, but can be massive from hypertrophied bronchial arteries

— Dyspnea on exertion, wheeze

— Pleuritic chest pain during exacerbations

— Fatigue, weight loss, low-grade fever

— Rhinosinusitis (think PCD or CVID if comorbid)

— Childhood infections: severe pneumonia, pertussis, measles, TB exposure

— Sinopulmonary infections since infancy → PCD or CF

— Infertility (men) or situs inversus → Kartagener/PCD

— GI symptoms, pancreatic insufficiency → CF

— Joint pain, dry eyes/mouth → RA, Sjögren

— Asthma + brown mucus plugs + eosinophilia → ABPA

— IBD, especially ulcerative colitis

— Recurrent sinopulmonary + GI infections → CVID

— Aspiration risk: stroke, dysphagia, GERD, alcohol use

— Occupational/environmental: hot tub use (NTM), inhaled toxins

— Family history of CF, PCD, immunodeficiency

Key distinction: Bronchiectasis cough is chronic and productive every day; asthma cough is episodic and often dry; COPD cough is productive but smoking-related. A nonsmoker with daily purulent sputum is bronchiectasis until proven otherwise.

Board pearl: A young adult with chronic sinusitis, otitis media, infertility, and bronchiectasis → order nasal nitric oxide (low in PCD) and consider ciliary biopsy/genetic testing. Situs inversus is present in ~50% of PCD (Kartagener subset).

Cardinal symptom triad:

Other symptoms to elicit:

Exacerbation definition (consensus 2017): Deterioration in ≥3 of 6 symptoms for ≥48 hours — cough, sputum volume/consistency, sputum purulence, dyspnea/exercise tolerance, fatigue/malaise, hemoptysis — requiring antibiotic change.

Targeted history checklist (etiologic yield):

Physical Exam Findings and Functional Assessment

— Often well-appearing between exacerbations

— Cachexia or low BMI in advanced disease, CF, or NTM

— Tall, thin, scoliotic body habitus classic for NTM-MAC ("Lady Windermere")

— Tachypnea and hypoxia during exacerbations

— Fever may be low-grade or absent even with significant exacerbation

— Resting SpO₂ <92% suggests advanced disease — check ambulatory saturation

— Crackles (coarse, inspiratory) in 70% — often persistent and localized (do not clear with cough, unlike pneumonia)

— Wheezing or rhonchi in 30%

— Localized findings over affected lobes (commonly lower lobes, lingula, RML)

— Reduced breath sounds in atelectatic or fibrotic areas

— Digital clubbing (~3%, but high-yield) — suggests advanced disease, CF, or chronic suppuration

— Nasal polyps → CF or ABPA

— Anosmia → PCD

— Dextrocardia → Kartagener

— Joint deformities → RA-associated bronchiectasis

— Telangiectasias or cirrhosis stigmata → alpha-1 antitrypsin

— 6-minute walk test for desaturation and exercise capacity

— mMRC dyspnea scale at each visit

— Quality-of-life tools: QOL-B, Bronchiectasis Health Questionnaire

— Bronchiectasis Severity Index (BSI) and FACED score stratify mortality risk

Step 3 management: Document baseline exam findings (location of crackles, clubbing, weight, SpO₂) at diagnosis so you can detect deterioration over years of follow-up. Stable localized crackles are expected; new diffuse crackles, new clubbing, or weight loss should trigger reassessment for NTM, malignancy, or progression.

Board pearl: Clubbing in a known bronchiectasis patient should NOT be dismissed — consider superimposed lung cancer or chronic NTM/CF disease and obtain HRCT.

General appearance:

Vital signs:

Pulmonary exam:

Extrapulmonary clues:

Functional assessment (ambulatory Step 3 focus):

Diagnostic Workup — Initial Labs and Imaging

— High-resolution CT (HRCT) chest without contrast is the gold standard — must order this to confirm diagnosis

— Diagnostic criteria on HRCT:

· Bronchoarterial ratio >1 ("signet ring sign" — dilated bronchus larger than adjacent artery)

· Lack of bronchial tapering toward periphery

· Visualization of bronchi within 1 cm of pleura

— Associated features: mucus plugging, "tree-in-bud," bronchial wall thickening, mosaic attenuation, atelectasis

— Distribution clues:

· Upper lobe → CF, post-TB, ABPA, sarcoid

· Lower lobe → post-infectious, immunodeficiency, aspiration

· Central → ABPA, tracheobronchomegaly (Mounier-Kuhn)

· RML/lingula → MAC/NTM

— CBC with differential (eosinophilia → ABPA)

— Quantitative immunoglobulins (IgG, IgA, IgM) — screen for CVID

— Sweat chloride test if any CF features (or genetic testing); guidelines recommend CF testing in adults <40 with bronchiectasis

— Alpha-1 antitrypsin level

— Aspergillus-specific IgE, total IgE, Aspergillus precipitins → ABPA

— RF, anti-CCP, ANA if autoimmune features

— HIV testing

— Sputum culture for bacteria (routine + Pseudomonas)

— Sputum AFB smear and culture × 3 for NTM and TB

— Fungal culture if ABPA suspected

Step 3 management: PFTs at baseline and annually — typical pattern is obstructive (reduced FEV1/FVC) with or without bronchodilator response; restrictive or mixed patterns occur in advanced disease.

Board pearl: Signet ring sign on HRCT = pathognomonic for bronchiectasis. Memorize it.

Imaging — the diagnostic cornerstone:

Chest X-ray: Insensitive but may show "tram tracks," ring shadows, or honeycombing in advanced disease — do not rule out bronchiectasis based on a normal CXR.

Initial labs (every newly diagnosed patient — etiologic workup):

Microbiologic workup:

Diagnostic Workup — Advanced and Etiology-Specific Studies

— Young patient, severe disease, family history, or recurrent NTM

— Failure to respond to optimized standard therapy

— Need to address modifiable etiology (changes management in ~40%)

— Sweat chloride (≥60 mmol/L diagnostic; 30–59 intermediate)

— CFTR genetic testing (panel for common mutations, then expanded sequencing)

— Nasal potential difference if equivocal

— Nasal nitric oxide (low in PCD) — best screening test in adults

— Ciliary ultrastructure on nasal/bronchial biopsy (electron microscopy)

— Genetic panel (>40 known genes)

— Quantitative immunoglobulins

— IgG subclasses (IgG2 deficiency)

— Specific antibody response to pneumococcal and tetanus vaccines (give vaccine, recheck titers 4–8 wks)

— Lymphocyte subsets, HIV

— Asthma, central bronchiectasis, total IgE >1000 IU/mL, elevated Aspergillus-specific IgE/IgG, eosinophilia >500, pulmonary infiltrates

— Clinical: symptoms + radiographic features (nodular/bronchiectatic or cavitary)

— Microbiologic: ≥2 positive sputum cultures OR 1 positive BAL OR 1 positive biopsy with granulomas

— Reserved for: focal disease (rule out obstruction/tumor/foreign body), inability to expectorate, suspected NTM with negative sputum, hemoptysis localization

— Esophagram/pH probe if reflux/aspiration suspected

— Echocardiogram if pulmonary HTN suspected

Key distinction: A single positive NTM sputum culture is not diagnostic — requires ≥2 positive cultures from separate sputa plus clinical/radiographic criteria. Don't treat colonization.

Board pearl: Always send sputum AFB ×3 in newly diagnosed bronchiectasis — NTM coexists in 10–20%.

When to expand workup:

Cystic fibrosis evaluation (any adult <40, or any age with classic features):

Primary ciliary dyskinesia evaluation:

Immunodeficiency workup:

ABPA criteria (Rosenberg-Patterson, simplified):

NTM workup (ATS/IDSA criteria for pulmonary NTM disease):

Bronchoscopy with BAL:

Other:

Risk Stratification and Management Logic

— Bronchiectasis Severity Index (BSI): age, BMI, FEV1%, hospitalization in past 2 years, exacerbations in past year, MRC dyspnea, Pseudomonas colonization, other organism colonization, radiologic extent (≥3 lobes or cystic). Score → mortality and hospitalization risk.

— FACED score: FEV1, Age, Chronic Colonization (Pseudomonas), Extension (lobes), Dyspnea.

— Pseudomonas colonization → worse prognosis, more exacerbations, target with eradication and chronic suppression

— Frequent exacerbations (≥3/year) → candidates for chronic macrolide

— NTM colonization → avoid azithromycin monotherapy (induces resistance)

— Severe airflow obstruction (FEV1 <30%) → consider transplant referral

1. Treat the underlying cause (CF modulators, IVIG for CVID, steroids/antifungals for ABPA, NTM-directed therapy)

2. Airway clearance (chest physiotherapy, PEP/flutter devices, hypertonic saline)

3. Manage infection (eradicate new Pseudomonas, suppress chronic infection, treat exacerbations)

4. Reduce inflammation/exacerbations (chronic macrolide, pulmonary rehab, vaccines)

— Step 1: Education, vaccines, smoking cessation, airway clearance daily, pulmonary rehab

— Step 2: Add mucoactive agent (hypertonic saline 7%) if persistent symptoms

— Step 3: Add inhaled bronchodilator if airflow obstruction or pre–airway clearance

— Step 4: Treat colonization (eradicate Pseudomonas)

— Step 5: Chronic macrolide if ≥3 exacerbations/year

— Step 6: Inhaled antibiotics for chronic Pseudomonas with frequent exacerbations

— Step 7: Consider surgery (focal disease) or transplant

Step 3 management: Inhaled corticosteroids are NOT routinely indicated in bronchiectasis unless there is coexisting asthma or COPD with eosinophilia. They increase pneumonia and NTM risk.

Board pearl: Pseudomonas colonization = strongest single predictor of mortality in bronchiectasis. Aggressive eradication on first isolation.

Severity scoring tools (use at diagnosis and annually):

Risk modifiers that drive therapy:

Four pillars of chronic management (memorize):

Stepwise outpatient approach:

Pharmacotherapy — Chronic Maintenance Regimens

— Hypertonic saline 7% nebulized BID — improves mucus clearance, reduces exacerbations

— Pretreat with short-acting bronchodilator (albuterol) to prevent bronchospasm

— Mannitol inhaled powder is alternative (not first-line in US)

— Dornase alfa (DNase) is contraindicated in non-CF bronchiectasis — worsens outcomes (key Step 3 distinction from CF!)

— SABA/LABA if reversible obstruction or symptomatic dyspnea

— LAMA may be useful if coexisting COPD features

— Indication: ≥3 exacerbations/year despite optimized clearance

— Azithromycin 250–500 mg three times weekly (or 250 mg daily) for ≥6 months

— Evidence: BAT, BLESS, EMBRACE trials → ~50% exacerbation reduction

— Before starting: rule out active NTM (sputum AFB ×3), check baseline ECG (QTc), LFTs, audiogram if long-term

— Monitor: QTc, hearing, LFTs, NTM cultures every 6–12 months

— Tobramycin inhaled (TOBI) 300 mg BID, 28 days on/28 days off

— Alternatives: aztreonam inhaled, colistin

— Indication: chronic Pseudomonas + frequent exacerbations

— Not FDA-approved for non-CF bronchiectasis but used per guidelines

— Sputum culture, then empiric antibiotics × 14 days (longer than typical)

— If no prior culture: amoxicillin-clavulanate or doxycycline

— If Pseudomonas-colonized: ciprofloxacin PO or IV anti-pseudomonal (pip-tazo, cefepime)

— H. influenzae and M. catarrhalis common; cover accordingly

Board pearl: Never start chronic azithromycin without ruling out NTM — monotherapy induces macrolide resistance and ruins future NTM treatment options.

Airway clearance pharmacotherapy:

Bronchodilators:

Chronic macrolide therapy (game-changer for frequent exacerbators):

Inhaled antibiotics for chronic Pseudomonas:

Treating exacerbations (acute):

ABPA-specific: Oral prednisone 0.5 mg/kg/day taper × 3–6 months ± itraconazole

NTM-MAC pulmonary disease: Triple therapy — azithromycin + rifampin + ethambutol, ≥12 months after culture conversion

Procedures and Advanced Interventions

— Goal: prevent chronic colonization, which predicts mortality

— Regimen: oral ciprofloxacin 750 mg BID × 2 weeks + inhaled tobramycin × 4–12 weeks

— Alternative: IV anti-pseudomonal × 2 weeks + inhaled antibiotic

— Confirm eradication with sputum cultures at 3, 6, 12 months

— Indication: massive hemoptysis (>100–200 mL in 24 hr or hemodynamic instability)

— First-line over surgery; success rate ~85%

— Recurrence common; may need repeat

— Watch for spinal cord ischemia (rare) from anterior spinal artery off bronchial circulation

— Indication: focal/localized bronchiectasis with persistent symptoms despite optimal medical therapy OR recurrent hemoptysis not controlled by BAE OR localized destroyed lobe with NTM

— Requires adequate FEV1 reserve (postoperative predicted FEV1 >40%)

— Preserve as much functional lung as possible

— Refer when FEV1 <30% predicted, rapid decline, severe hypoxemia/hypercapnia, pulmonary HTN, or massive recurrent hemoptysis

— Bilateral lung transplant required (suppurative disease)

— In CF: refer earlier given rapid trajectory

— Strong evidence for improved exercise capacity, dyspnea, QOL

— Refer all symptomatic patients with mMRC ≥2

— Oscillating PEP devices (Acapella, Aerobika, Flutter)

— High-frequency chest wall oscillation vest

— Active cycle of breathing, autogenic drainage

— Annual influenza

— PCV20 (or PCV15 + PPSV23 sequence)

— COVID-19 per current guidance

— RSV vaccine if ≥60 years

— Tdap, zoster

CCS pearl: For massive hemoptysis admit to ICU, position bleeding side down, secure airway (large-bore ETT for possible bronchoscopy), reverse coagulopathy, then order bronchial artery embolization — not emergent surgery.

Pseudomonas eradication protocol (first isolation):

Bronchial artery embolization (BAE):

Surgical resection (lobectomy/segmentectomy):

Lung transplantation:

Pulmonary rehabilitation:

Airway clearance device adjuncts:

Vaccination (every patient):

Special Populations — Elderly and Renal/Hepatic Impairment

— Slower diagnostic recognition — symptoms often attributed to "aging" or "COPD"

— Greater NTM prevalence — low threshold for sputum AFB

— Polypharmacy concerns:

· Azithromycin + QT-prolonging drugs (citalopram, ondansetron, methadone, antipsychotics) — review meds before initiating

· Fluoroquinolones: tendinopathy, aortic aneurysm risk, dysglycemia, CNS effects, C. diff

— Frailty assessment: gait speed, sarcopenia — affects rehab tolerance and transplant candidacy

— Bone health: chronic prednisone (ABPA) → DEXA, vitamin D, bisphosphonate prophylaxis if appropriate

— Falls risk if hypoxia, deconditioning

— Aminoglycosides (tobramycin): Inhaled has minimal systemic absorption, but reduce IV dose and monitor levels; check baseline and weekly creatinine, audiology if prolonged

— Ciprofloxacin: reduce dose if CrCl <50

— Ethambutol (NTM): renally cleared — dose adjust to prevent optic neuritis

— Colistin (inhaled or IV): nephrotoxic; avoid IV if alternatives exist

— Avoid NSAIDs in CKD bronchiectasis patients

— Azithromycin: caution in severe hepatic dysfunction; monitor LFTs

— Rifampin (NTM): hepatotoxic and major CYP3A4 inducer — review drug interactions (warfarin, DOACs, statins, OCPs, immunosuppressants)

— Itraconazole (ABPA): hepatotoxic, check LFTs, drug interactions, negative inotrope (avoid in HF)

— Hemoptysis history complicates AF or VTE management — individualize, often hold or reduce intensity during acute bleeding; consult cardiology/hematology

Step 3 management: In an elderly bronchiectasis patient starting chronic azithromycin, obtain baseline ECG (QTc), audiogram, LFTs, and sputum AFB ×3; reassess every 6–12 months. Stop if QTc >500 ms or hearing loss develops.

Board pearl: Ethambutol → optic neuritis (red-green color blindness). Baseline + monthly visual acuity and color vision exams.

Elderly patients (most common bronchiectasis demographic):

Renal impairment dosing adjustments:

Hepatic impairment:

Anticoagulation considerations:

Special Populations — Pregnancy, Pediatrics, and Genetic Subgroups

— Preconception counseling essential; refer to high-risk OB and pulmonology

— Optimize FEV1 before conception; FEV1 <50% predicts poor outcomes

— Continue airway clearance throughout pregnancy

— Vaccines: inactivated flu, Tdap (27–36 weeks), COVID — all safe

— Antibiotic safety:

· Safe: penicillins, cephalosporins, azithromycin (Category B), aztreonam

· Avoid: tetracyclines (teeth/bone), fluoroquinolones (cartilage — relative), aminoglycosides systemic (ototoxicity to fetus), sulfa near term

· Inhaled tobramycin: limited data, minimal systemic absorption; weigh benefits

— Hypoxemia harms fetus — target SpO₂ ≥95%

— Genetic counseling if CF/PCD — partner carrier screening

— Always investigate underlying cause: CF, PCD, immunodeficiency, foreign body, aspiration

— Reversibility possible in children with early aggressive therapy

— Transition to adult pulmonology between 18–21 with structured handoff

— CFTR modulators (elexacaftor/tezacaftor/ivacaftor — Trikafta) for eligible mutations (F508del-containing) — dramatically improves FEV1, reduces exacerbations, weight gain

— Pancreatic enzyme replacement, fat-soluble vitamins

— CF-related diabetes screening annually after age 10

— Annual liver disease screening

— DNase IS indicated in CF (opposite of non-CF)

— Genetic counseling — autosomal recessive

— Hearing assessment (chronic otitis media common)

— Fertility counseling

— IVIG or SCIG replacement — reduces infections and slows progression

— Oral steroid taper; itraconazole; monitor IgE trend

Key distinction: DNase (dornase alfa) is indicated in CF bronchiectasis but contraindicated in non-CF bronchiectasis — classic Step 3 distractor.

Board pearl: A pregnant patient with bronchiectasis and chronic Pseudomonas — switch to azithromycin/aztreonam-inhaled regimen and avoid fluoroquinolones unless benefits outweigh risks.

Pregnancy:

Pediatric bronchiectasis (Step 3 may test transition-of-care concepts):

CF-specific (adults):

PCD-specific:

Immunodeficiency (CVID):

ABPA:

Complications and Adverse Outcomes

— Acute exacerbations (most common) — primary driver of QOL decline and mortality

— Hemoptysis: ranges from blood-streaked sputum to massive (>200 mL/24 hr); source is hypertrophied bronchial arteries (systemic pressure)

— Pneumonia — recurrent, often with resistant organisms

— Pneumothorax from cyst rupture (more in CF)

— Respiratory failure — chronic hypoxemia, hypercapnia in advanced disease

— Pulmonary hypertension from chronic hypoxia → cor pulmonale, RV failure

— Chronic Pseudomonas colonization — accelerates FEV1 decline, increases exacerbations, mortality

— NTM superinfection — MAC, M. abscessus; complicates 10–20%

— Aspergillus colonization → ABPA flares

— MRSA, multidrug-resistant gram-negatives

— Secondary AA amyloidosis from chronic inflammation → nephrotic syndrome, renal failure (rare but classic exam fact)

— Weight loss/cachexia

— Osteoporosis (chronic inflammation, steroids, vitamin D deficiency, hypoxia)

— Depression and anxiety — screen routinely

— Anemia of chronic disease

— Macrolide: QT prolongation, hearing loss, hepatotoxicity, NTM resistance

— Fluoroquinolones: tendinopathy, aortic aneurysm, C. diff, dysglycemia, neuropathy, QT

— Aminoglycosides: nephro- and ototoxicity (mostly with systemic, less with inhaled)

— Inhaled antibiotics: bronchospasm — pretreat with bronchodilator

— Chronic corticosteroids (ABPA): osteoporosis, diabetes, cataracts, adrenal suppression

— Reduced exercise tolerance, work absenteeism

— High healthcare utilization

Board pearl: Secondary AA amyloidosis presenting with proteinuria in a long-standing bronchiectasis patient — classic boards trap. Workup: serum/urine protein electrophoresis, fat pad biopsy with Congo red staining.

Step 3 management: Screen for anxiety/depression (PHQ-9, GAD-7) annually — comorbid in ~30% and affects adherence to chronic airway clearance.

Pulmonary complications:

Microbiologic complications:

Systemic complications:

Treatment-related complications:

Functional/social:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Stable patient with mild-moderate exacerbation: oral antibiotics × 14 days, intensify airway clearance, close follow-up at 1–2 weeks

— Failure of outpatient antibiotic therapy

— Hypoxemia (SpO₂ <92% room air, new oxygen requirement)

— Inability to tolerate orals or maintain hydration

— Suspected resistant organism requiring IV therapy

— Significant hemoptysis (>30 mL/24 hr but stable)

— Comorbidities decompensating (HF, diabetes)

— Frailty, poor home support, transportation barriers

— Massive hemoptysis (>200 mL/24 hr or hemodynamic instability)

— Respiratory failure requiring NIV or intubation

— Septic shock from pneumonia

— Severe hypercapnia with altered mental status

— Order: CBC, CMP, blood cultures ×2, sputum gram stain/culture, sputum AFB, ABG, CXR, ECG, type and screen

— Empiric IV antibiotics covering Pseudomonas if colonized (piperacillin-tazobactam OR cefepime); add MRSA coverage (vancomycin) if prior MRSA or severe illness

— Aggressive airway clearance: nebulized hypertonic saline, chest PT, suctioning

— Supplemental O₂ to SpO₂ 88–92% (avoid hyperoxia if chronic CO₂ retention)

— NIV (BiPAP) for hypercapnic respiratory failure

— VTE prophylaxis (consider risk with hemoptysis)

— Hold antiplatelets/anticoagulants if active hemoptysis

— Position bleeding side down (protect contralateral lung)

— Secure airway with large-bore ETT (≥8.0) for therapeutic bronchoscopy

— Reverse coagulopathy; transfuse PRBCs

— Emergent bronchial artery embolization (interventional radiology consult)

— Surgery reserved for embolization failure

— Pulmonology (all bronchiectasis patients longitudinally)

— Infectious disease for NTM, MDR organisms

— Thoracic surgery for focal disease or transplant evaluation

— Interventional radiology for hemoptysis

CCS pearl: Hemoptysis + bronchiectasis → bronchial artery embolization is first-line, not surgery.

Outpatient (ambulatory) — typical management:

Admit to general medical floor:

Admit to ICU:

CCS-flavored inpatient workflow for severe exacerbation:

Massive hemoptysis algorithm:

Specialist consults:

Key Differentials — Same-Category (Chronic Productive Cough) Causes

— Smoker, productive cough ≥3 months/year × 2 years

— Obstruction on PFTs, normal HRCT (no bronchial dilation)

— Coexists with bronchiectasis in ~30% of COPD patients ("BCOS overlap")

— Key distinction: HRCT differentiates — bronchiectasis has bronchoarterial ratio >1

— Bronchiectasis IS a feature of CF — they are not mutually exclusive

— Upper lobe predominance, pancreatic insufficiency, infertility, sweat chloride ≥60

— Younger age at presentation but increasing adult diagnoses

— Episodic wheeze, reversible obstruction, eosinophilia

— ABPA can cause overlap with bronchiectasis

— Self-limited; resolves over weeks to months

— Constitutional symptoms, weight loss, night sweats

— Upper lobe cavitation, fibrosis, bronchiectasis after healed disease

— Always rule out active TB before macrolide

— MAC, M. abscessus; often coexists with bronchiectasis

— Diagnose by ATS/IDSA criteria (≥2 positive sputum cultures + clinical/radiographic)

— Acute or subacute; cavitary lesion; foul-smelling sputum

— Sinusitis + small airway disease; responds to chronic erythromycin

— Cavitary lesion with fungus ball; chronic cough, hemoptysis; positive Aspergillus IgG

— Dysphagia, GERD, neurologic disease; lower lobe/posterior segment predilection

Key distinction: Chronic bronchitis = clinical/PFT diagnosis (no anatomic dilation required). Bronchiectasis = anatomic diagnosis on HRCT (bronchial dilation required). They can coexist.

Board pearl: A nonsmoker with COPD-like presentation → think bronchiectasis or alpha-1 antitrypsin deficiency; both warrant HRCT and A1AT level.

Chronic bronchitis / COPD:

Cystic fibrosis:

Chronic asthma with mucus hypersecretion:

Post-infectious bronchitis:

Pulmonary tuberculosis (active or post-TB sequelae):

Non-tuberculous mycobacterial disease:

Lung abscess:

Diffuse panbronchiolitis (rare, Asian populations):

Aspergilloma / chronic pulmonary aspergillosis:

Recurrent aspiration pneumonitis:

Key Differentials — Other-Category Causes

— Left heart failure — orthopnea, PND, frothy pink sputum, BNP elevation, bibasilar crackles

— Pulmonary edema mimics infection with productive cough

— Key distinction: echocardiogram and BNP; HRCT shows septal thickening, not bronchial dilation

— ACE inhibitors — dry cough in 5–20%; resolves with discontinuation

— Amiodarone pulmonary toxicity, methotrexate pneumonitis

— Allergic or non-allergic rhinitis, sinusitis

— Throat clearing, cobblestoning of posterior pharynx

— Trial of intranasal steroid + antihistamine

— Nocturnal cough, sour taste, heartburn (or silent reflux)

— Trial of PPI, lifestyle modification, esophageal pH testing

— Progressive dyspnea, dry cough, Velcro crackles, clubbing

— HRCT: reticulation, honeycombing, ground-glass — different pattern

— Traction bronchiectasis from fibrosis can mimic primary bronchiectasis but distribution and surrounding fibrosis distinguish

— Hilar lymphadenopathy, upper lobe disease, extrapulmonary findings (uveitis, erythema nodosum, hypercalcemia)

— Can cause traction bronchiectasis

— Lung cancer, carcinoid tumor, foreign body, broncholithiasis, mucoid impaction

— Bronchoscopy mandatory if focal bronchiectasis on HRCT

— Post-transplant, autoimmune (RA), inhalational injury

— EGPA, chronic eosinophilic pneumonia — peripheral eosinophilia, ANCA

— Absent during sleep, no nocturnal symptoms

Step 3 management: Focal bronchiectasis on HRCT mandates bronchoscopy to rule out endobronchial obstruction (tumor, foreign body) — never assume idiopathic.

Board pearl: A 60-year-old with new focal RLL bronchiectasis and unintentional weight loss → bronchoscopy to rule out endobronchial carcinoid or NSCLC.

Cardiac etiologies of chronic cough:

Drug-induced cough:

Upper airway cough syndrome (post-nasal drip):

GERD-related cough:

Interstitial lung disease (ILD):

Sarcoidosis:

Endobronchial obstruction (focal bronchiectasis clue):

Bronchiolitis (obliterative, follicular):

Eosinophilic lung disease:

Psychogenic/habit cough:

Secondary Prevention and Long-Term Plan

— Influenza vaccine annually (inactivated; live attenuated contraindicated if immunocompromised)

— Pneumococcal: PCV20 alone OR PCV15 followed by PPSV23 ≥1 year later

— COVID-19 per current CDC schedule

— RSV vaccine if ≥60 years

— Tdap every 10 years

— Shingles (Shingrix) if ≥50

— Hepatitis B if at risk; consider if on biologics

— Nicotine replacement, varenicline, bupropion

— Document at every visit (counseling is a quality measure)

— Avoid secondhand smoke and biomass exposure

— Avoid hot tubs and indoor swimming pools (NTM aerosolization risk)

— Filter and treat household water if NTM concern

— Indoor air quality, avoid mold exposure

— Maintain BMI ≥22 (low BMI predicts mortality)

— High-protein, calorie-adequate diet

— Vitamin D supplementation; calcium for bone health

— Pancreatic enzyme replacement if CF

— DEXA baseline, repeat every 2 years

— Vitamin D, calcium; bisphosphonate if osteoporosis

— Hypertonic saline 7% nebulized BID

— Airway clearance device daily

— Azithromycin 500 mg M/W/F if frequent exacerbator (after NTM rule-out)

— Inhaled tobramycin cycles if chronic Pseudomonas

— Bronchodilators PRN

— Avoid sedatives that suppress cough

— Written action plan with sputum color/volume triggers

— Home supply of "rescue" antibiotics for early exacerbation (per individualized plan)

— Emergency contact protocol

Step 3 management: Provide a written exacerbation action plan — patients self-initiate culture-directed antibiotics at first sign of sputum change. Reduces hospitalization.

Board pearl: Avoid hot tubs in patients with bronchiectasis — major NTM-MAC reservoir ("hot tub lung").

Vaccination schedule (every bronchiectasis patient):

Smoking cessation:

Environmental modifications:

Nutrition:

Bone health:

Chronic medication summary (discharge/maintenance):

Self-management plan:

Follow-Up, Monitoring, and Rehabilitation

— Mild-moderate stable: pulmonology every 6–12 months

— Severe or chronic Pseudomonas: every 3–6 months

— Post-exacerbation: 2–4 week follow-up to confirm resolution

— Symptom diary, exacerbation count, sputum changes

— mMRC dyspnea, 6MWT

— Weight, BMI, nutritional status

— Medication adherence and technique (nebulizer, devices)

— Adverse effects (hearing, vision, tendons if on quinolones)

— Depression/anxiety screening

— Spirometry (PFTs) annually — track FEV1 decline (>50 mL/year is excessive)

— Sputum culture annually + with each exacerbation (bacteria + AFB + fungi)

— CBC, CMP

— Vitamin D if deficient

— Repeat HRCT every 2–5 years OR with clinical worsening, new symptoms, or hemoptysis

— Not for routine surveillance every year (radiation exposure)

— Chronic azithromycin: ECG (QTc) at baseline and as needed, LFTs every 6 months, audiogram annually, sputum AFB every 6–12 months

— Inhaled tobramycin: audiogram and renal function periodically

— Chronic prednisone (ABPA): glucose, BMD, BP, lipids, eye exam

— Refer all symptomatic patients (mMRC ≥2)

— 6–8 week program; repeat as needed

— Improves dyspnea, exercise tolerance, QOL

— Maintenance program after structured rehab

— Adherence to airway clearance is the single biggest modifiable factor — review at every visit

— Inhaler technique review (high error rate)

— Mental health support — referral to therapy if depression/anxiety identified

— Post-hospitalization: medication reconciliation, follow-up call within 48–72 hours, clinic visit within 7–14 days

— Pediatric to adult care: structured transition between 18–21

Step 3 management: A patient on chronic azithromycin develops a new productive cough — resend sputum AFB ×3 before escalating to detect emergent NTM. Routine NTM surveillance every 6–12 months is standard.

Board pearl: FEV1 decline >50 mL/year is excessive — trigger reassessment for new Pseudomonas, NTM, ABPA flare, or alternative diagnosis.

Visit cadence:

At each visit, assess:

Annual testing:

Periodic imaging:

Monitoring for specific therapies:

Pulmonary rehabilitation:

Counseling and adherence:

Transitions of care:

Ethical, Legal, and Patient Safety Considerations

— Bronchial artery embolization — discuss rare but serious risk of spinal cord ischemia/paralysis (from anterior spinal artery off bronchial circulation), even in emergent settings; document discussion or surrogate consent

— Lung transplantation: lengthy informed consent including mortality on waitlist, post-transplant infection/rejection risk, lifelong immunosuppression

— Chronic macrolide: discuss hearing loss, QT prolongation, NTM resistance risks before starting; ensure shared decision-making

— Hospital discharge after exacerbation is high-risk window:

· Medication reconciliation — reconcile inhaled antibiotics, nebulizer schedules, oral antibiotic duration

· Confirm sputum culture results communicated to outpatient pulmonologist

· Schedule 7–14 day follow-up before discharge

· Provide written action plan and refill prescriptions

· Verify durable medical equipment (nebulizer, vest, oxygen) at home

— Pediatric-to-adult transition: structured handoff process between 18–21

— Active TB is mandatorily reportable to public health (do not confuse with NTM, which is not reportable in most states)

— Multidrug-resistant organisms — institutional infection control reporting

— CF and PCD diagnoses have family implications — offer genetic counseling and carrier testing for relatives and reproductive partners

— GINA protects against genetic discrimination in health insurance and employment (not life/disability)

— Polypharmacy and QT prolongation: review meds before macrolide initiation; pharmacist consult helpful

— Antibiotic stewardship — avoid unnecessary courses; tailor to cultures

— Fall risk assessment in hypoxic/frail patients

— Home oxygen safety counseling (no smoking, secured tanks)

— Discuss goals of care in advanced disease (FEV1 <30%, recurrent hospitalizations, declining functional status)

— Advance directives, code status, palliative care referral

— Hospice eligibility when transplant not an option and decline is progressive

Step 3 management: A patient with end-stage bronchiectasis not a transplant candidate, with three hospitalizations in 6 months and progressive cachexia → palliative care consultation and goals-of-care discussion are appropriate alongside continued disease-directed care.

Board pearl: Active TB is reportable; NTM is not — common Step 3 trap.

Informed consent edge cases:

Transition-of-care safety:

Mandatory reporting and public health:

Genetic testing and counseling:

Patient safety:

End-of-life / advance care planning:

High-Yield Associations and Rapid-Fire Clinical Facts

— Kartagener syndrome: situs inversus + chronic sinusitis + bronchiectasis (PCD subset, ~50% of PCD patients)

— Young syndrome: bronchiectasis + sinusitis + obstructive azoospermia (normal cilia and sweat chloride)

— Mounier-Kuhn syndrome: tracheobronchomegaly with central bronchiectasis

— Williams-Campbell syndrome: congenital cartilage deficiency → cystic bronchiectasis

— Lady Windermere syndrome: RML/lingular MAC infection in thin elderly nonsmoking women

— Swyer-James-MacLeod syndrome: unilateral hyperlucent lung post-childhood infection with bronchiectasis

— Signet ring sign = dilated bronchus + adjacent artery on cross-section

— Tree-in-bud = small airway impaction (infection, NTM, aspiration)

— Tram tracks on CXR = parallel bronchial walls

— Upper lobe distribution → CF, ABPA, TB, sarcoid

— RML/lingula → MAC

— Most common bacteria: H. influenzae (most common overall), Pseudomonas aeruginosa (worst prognosis), S. pneumoniae, S. aureus, M. catarrhalis

— NTM most common: M. avium complex; M. abscessus (hardest to treat)

— Fungi: Aspergillus fumigatus → ABPA

— DNase: YES in CF, NO in non-CF bronchiectasis

— Inhaled corticosteroids: not routine; only if asthma/COPD overlap

— Azithromycin chronic dosing: 250–500 mg three times weekly

— Pseudomonas eradication: cipro PO + inhaled tobramycin

— BSI and FACED — know components: age, FEV1, BMI, hospitalizations, exacerbations, dyspnea, Pseudomonas, radiologic extent

— CF: CFTR gene, chromosome 7, F508del most common

— PCD: nasal NO low; ciliary EM diagnostic

— CVID: low IgG + low IgA or IgM + poor vaccine response

— Secondary AA amyloidosis with proteinuria — chronic suppurative inflammation

— Pulmonary HTN/cor pulmonale in advanced disease

— Massive hemoptysis from bronchial arteries (systemic, high pressure)

Board pearl: A patient with bronchiectasis + nephrotic-range proteinuria → renal biopsy with Congo red staining to evaluate for secondary AA amyloidosis.

Classic syndromes and triads:

Imaging pearls:

Microbiology associations:

Drug pearls:

Scoring tools:

Genetic/immunologic:

Complication pearls:

Board Question Stem Patterns

— Thin elderly woman, lifelong nonsmoker, chronic cough, RML/lingular nodular bronchiectasis on HRCT

— Answer path: Sputum AFB ×3 → diagnose MAC → treat with azithromycin + rifampin + ethambutol ≥12 months after culture conversion

— Trap: Starting azithromycin alone (induces resistance)

— Asthmatic with brown mucus plugs, peripheral eosinophilia, central bronchiectasis, IgE >1000

— Answer: ABPA → oral prednisone taper ± itraconazole

— Adult <40 with bronchiectasis, sinusitis, possibly infertility or pancreatic insufficiency

— Answer: Sweat chloride test → CF workup

— Young patient with bronchiectasis, situs inversus, infertility, chronic sinusitis

— Answer: Primary ciliary dyskinesia — nasal nitric oxide screening, ciliary biopsy

— Recurrent sinopulmonary infections + bronchiectasis + low immunoglobulins

— Answer: IVIG replacement therapy

— Bronchiectasis patient with sudden 300 mL hemoptysis, hypoxic

— Answer: Position bleeding side down, secure airway with large ETT, type and screen, bronchial artery embolization (not surgery first)

— ≥3 exacerbations/year, chronic Pseudomonas

— Answer: Rule out NTM with sputum AFB ×3 → start chronic azithromycin + consider inhaled tobramycin

— New localized bronchiectasis, weight loss, smoker

— Answer: Bronchoscopy to rule out endobronchial tumor/obstruction

— Answer: Secondary AA amyloidosis — renal biopsy with Congo red

— Patient with non-CF bronchiectasis given DNase

— Answer: Discontinue DNase (contraindicated in non-CF)

— Answer: Switch to safer alternative (azithromycin, beta-lactam, aztreonam inhaled)

Board pearl: When the stem mentions "improvement on antibiotics but recurrent symptoms" + chronic productive cough + crackles in same area — think bronchiectasis and order HRCT.

Stem pattern 1 — The Lady Windermere:

Stem pattern 2 — The "asthma" that isn't responding:

Stem pattern 3 — The young adult with sinopulmonary infections:

Stem pattern 4 — The Kartagener:

Stem pattern 5 — The CVID patient:

Stem pattern 6 — Massive hemoptysis:

Stem pattern 7 — Chronic Pseudomonas with frequent exacerbations:

Stem pattern 8 — Focal bronchiectasis in older adult:

Stem pattern 9 — Proteinuria in long-standing bronchiectasis:

Stem pattern 10 — Wrong-drug trap:

Stem pattern 11 — Pregnant patient with bronchiectasis on cipro:

One-Line Recap

Bronchiectasis is a chronic, syndromic airway disease defined anatomically by HRCT (bronchoarterial ratio >1, signet ring sign) and managed longitudinally through the four pillars — treating the underlying etiology, daily airway clearance, infection control (eradicate new Pseudomonas, suppress chronic colonization, treat exacerbations for 14 days), and exacerbation reduction (chronic macrolide after ruling out NTM) — while preventing complications through vaccination, pulmonary rehab, and structured follow-up.

— HRCT is gold standard; signet ring sign is pathognomonic

— Always pursue etiologic workup: CF (sweat chloride <40), PCD (nasal NO), CVID (immunoglobulins + vaccine titers), ABPA (IgE, Aspergillus-specific IgE, eosinophilia), NTM (sputum AFB ×3), alpha-1 antitrypsin, autoimmune panel, HIV

— Focal bronchiectasis demands bronchoscopy to rule out obstruction

— Daily hypertonic saline 7% + airway clearance device

— DNase: YES in CF, NO in non-CF (high-yield distinction)

— Pseudomonas first isolation: cipro PO × 2 weeks + inhaled tobramycin to eradicate

— Chronic azithromycin 3×/week if ≥3 exacerbations/year (after ruling out NTM — never miss this step)

— Exacerbations: 14-day antibiotic course tailored to prior cultures

— Vaccines: influenza, PCV20, COVID, RSV, Tdap, zoster

— Pulmonary rehab for all symptomatic patients

— Massive hemoptysis → ICU, side down, large ETT, bronchial artery embolization

— Focal destroyed lobe or refractory hemoptysis → surgical resection

— FEV1 <30%, rapid decline, or recurrent severe disease → lung transplant referral

— Macrolide monotherapy in occult NTM induces resistance

— DNase in non-CF bronchiectasis worsens outcomes

— Secondary AA amyloidosis presenting with proteinuria

— Active TB reportable; NTM not

Step 3 management: Bronchiectasis care is ambulatory and longitudinal — every clinic visit reassess symptoms, sputum, adherence, exacerbation frequency, and screening cultures, and tailor therapy to prevent the next exacerbation.

Diagnosis recap:

Management recap:

Escalation recap:

High-yield traps: